Who's next for a buyout? Pick your rumor; Astellas says Xtandi will fuel 25% profits hike;

@FiercePharma: Teva passed up an opportunity to buy Mylan target Perrigo: Globes. Report | Follow @FiercePharma

@EricPFierce: Alexion expanding in Ireland. Will spend $506M on its first biologics plant outside of U.S. News from FiercePharmaManufacturing | Follow @EricPFierce

> Not content with Alexion's ($ALXN) $8.4 billion deal to buy Synageva BioPharma ($GEVA) this week, deal-happy analysts are touting three biotech names oft mentioned in M&A rumors: Vertex ($VRTX), BioMarin ($BMRN) and Ariad ($ARIA). Report

> Japan's Astellas Pharma said upbeat U.S. sales--fueled by its prostate cancer drug Xtandi--will deliver a 25% increase in profits this fiscal year to 170 billion yen ($1.4 billion), on sales of 1.36 trillion yen. Report

> Scottish cost regulators gave the nod to 7 new medicines for use by NHS Scotland, including Takeda's new ulcerative colitis treatment Entyvio. Report

> Johnson & Johnson ($JNJ) is expanding its pediatric access program for the HIV medicine Prezista (darunavir), saying it will not enforce its patent rights in 128 low- and middle-income countries. Release

> AbbVie ($ABBV) will roll out new data from studies of 5 cancer meds at the American Society of Clinical Oncology meeting later this month. Release

Medical Device News

@FierceMedDev: HTG Molecular Diagnostics unveils $50M IPO for genomic profiling technology. FierceDiagnostics article | Follow @FierceMedDev

@VarunSaxena2: ICYMI yesterday: FDA approves Nevro device that eliminates side effect of spinal stimulation. Article | Follow @VarunSaxena2

@EmilyWFierce: Google signs on Harvard doc to lead bioinformatics study. News | Follow @EmilyWFierce

> Autonomic raises $38M to fund U.S. pivotal trial, EU marketing for headache microstimulator. News

> FDA grants priority review status in first-line glioblastoma for Medtronic, J&J-backed startup Novocure. More

Biotech News

@FierceBiotech: Pfizer continues its deal spree with a $600M option pact to buy AM-Pharma. News | Follow @FierceBiotech

@JohnCFierce: It's a great time to go shopping in Europe. Three deals in the last 24 hours, with U.S. biotechs buying into European companies. | Follow @JohnCFierce

> Analysts are souring fast on GlaxoSmithKline's defensive market crouch. Story

> Activists want Spectrum to dump its CEO and find a buyer. Article

> Juno beefs up its CAR-T arsenal with an $80M biotech buyout. Report

Pharma Manufacturing News

> 33 indicted for selling BMS' Abilify, Novartis' Gleevec in massive diversion scheme. Report

> Alexion to build $506M plant in Ireland, add 200 workers. News

> Hikma building its sterile injectable operation with Bedford equipment and products. Story

> Eisai to boost Indian API production to cut costs. Item

> Novartis' Sandoz expands Poland plant with packaging facility. Article

Pharma Asia News

> Australia negotiates pharmacy reimbursement increase as part of budget savings. Report

> Japan's Oncolys begins PhI trial of cancer drug licensed from Astellas. Item

> India eyes new manufacturing, clinical trial models to sell generics to Japan. More

> India's Punjab state goes its own way on drug price caps. Story

> Takeda, Orexigen end CV study for obesity drug Contrave. Article

Drug Delivery News

> Researchers turn to bacteria secretion systems to deliver proteins. Report

> Lilly hopes new drug delivery R&D center will prove useful in osteoporosis, diabetes arenas. More

> Supercooled nanoparticles offer targeted delivery approach. Story

> Gene editing player gets $25M in Series A round. Item

> Neuroderm stock up as FDA lifts hold on its subcutaneously delivered Parkinson's candidate. Article

And Finally... The White House warned insurance companies that they must cover all forms of female contraception, including the patch and intrauterine devices, without co-pays or other charges. Report

Suggested Articles

Move over, Roche. There’s a new small-cell lung cancer therapy on the scene, and it belongs to AstraZeneca.

Fujifilm says it is prepared to ramp up production of Avigan for any country that wants to try it as a potential treatment for COVID-19.

Gilead CEO promised to make remdesivir affordable, shortly after the company backed off its request for orphan status amid a public backlash.